Prelude Therapeutics (PRLD) Net Cash Flow (QoQ) (2020 - 2026)
Prelude Therapeutics (PRLD) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Prelude Therapeutics | 324.30 Mn | 179.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.97% |
| Dec 31, 2025 | -158.54% |
| Sep 30, 2025 | 244.46% |
| Jun 30, 2025 | -152.23% |
| Mar 31, 2025 | 1,974.25% |
| Dec 31, 2024 | 108.03% |
| Sep 30, 2024 | -634.89% |
| Jun 30, 2024 | 634.42% |
| Mar 31, 2024 | -106.22% |
| Dec 31, 2023 | 189.05% |
| Sep 30, 2023 | -227.96% |
| Jun 30, 2023 | 166.47% |
| Mar 31, 2023 | 42.08% |
| Dec 31, 2022 | -1,727.43% |
| Sep 30, 2022 | 241.81% |
| Jun 30, 2022 | -104.69% |
| Mar 31, 2022 | 177.51% |
| Dec 31, 2021 | 90.93% |
| Sep 30, 2021 | -1,317.62% |
| Jun 30, 2021 | -113.73% |